{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:13:17Z","timestamp":1788235997156,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-026-02742-0","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:56:23Z","timestamp":1783936583000},"page":"1615-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between SGLT2 inhibitors and reporting of phimosis\/paraphimosis: a comparative pharmacovigilance analysis of the WHO database"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-6001","authenticated-orcid":false,"given":"Jean-Louis","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2742_CR1","unstructured":"Powers AC, D\u2019Alesio D (2023) Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. In: Brunton LL, Knollmann BJ (eds) Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics, 14th edn. Mc Graw Hill, pp 1023\u20131047"},{"key":"2742_CR2","unstructured":"Eschenhagen T (2023) Therapy of Heart Failure. In: Brunton LL, Knollmann BJ, eds. Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics. 14th ed. Mc Graw Hill; :648\u2013666"},{"key":"2742_CR3","doi-asserted-by":"publisher","first-page":"109015","DOI":"10.1016\/j.jdiacomp.2025.109015","volume":"39","author":"A Del Zoppo","year":"2025","unstructured":"Del Zoppo A, Rovera C, Petralli G, Moriconi D, Solini A (2025) Urogenital side effects in male subjects with type 2 diabetes treated with SGLT-2 inhibitors: A single centre, longitudinal observation. J Diabetes Complications 39:109015","journal-title":"J Diabetes Complications"},{"key":"2742_CR4","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2337\/dc25-0693","volume":"48","author":"C Ljungberg","year":"2025","unstructured":"Ljungberg C, N\u00f8rgaard M, Vandenbroucke-Grauls C, Jakobsen JK, Charles MH, Potteg\u00e5rd A, Dalager-Pedersen M, S\u00f8rensen HT, Thomsen RW (2025) Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study. Diabetes Care 48:1774\u20131782","journal-title":"Diabetes Care"},{"key":"2742_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40264-025-01642-6","volume":"49","author":"JS Brand","year":"2026","unstructured":"Brand JS, Gauffin O, Sartori D, Fusaroli M, Sk\u00f6ld H, Bergvall T, Sandberg L, Wallberg M, Hjelmstr\u00f6m P, Nor\u00e9n GN (2026) VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines. Drug Saf 49:613\u2013629","journal-title":"Drug Saf"},{"key":"2742_CR6","unstructured":"MedDRA Medical Dictionary for Regulatory Activities MedDRA. https:\/\/www.meddra.org\/ (Accessed 1\/10\/2025)"},{"key":"2742_CR7","unstructured":"Anatomical Therapeutic Chemical (ATC) Classification. World Health Organization. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification (Accessed 1\/10\/2025)"},{"key":"2742_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908","journal-title":"Br J Clin Pharmacol"},{"key":"2742_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\u00e9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C (2024) The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf 47:585\u2013599","journal-title":"Drug Saf"},{"key":"2742_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1464-410X.2007.07274.x","volume":"101","author":"SJ Bromage","year":"2008","unstructured":"Bromage SJ, Crump A, Pearce I (2008) Phimosis as a presenting feature of diabetes. BJU Int 101:338\u2013340","journal-title":"BJU Int"},{"key":"2742_CR11","unstructured":"Silverberg B, Partin M, Clark R, Newman R Male Sexual Disorders: Penile Disorders. FP Essent 2025 May :552:13\u201320"},{"key":"2742_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00002018-200730080-00001","volume":"30","author":"M Hauben","year":"2007","unstructured":"Hauben M, Aronson JK (2007) Gold standards in pharmacovigilance: The Use of Definitive Anecdotal Reports of Adverse Drug Reactions as Pure Gold and High-Grade Ore. Drug Saf 30:645\u2013655","journal-title":"Drug Saf"},{"key":"2742_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.therap.2023.10.007","volume":"79","author":"JL Montastruc","year":"2024","unstructured":"Montastruc JL (2024) Drug-induced diseases: A worrying, neglected, preventable, serious and costly epidemic. Therapie 79:151\u2013154","journal-title":"Therapie"},{"key":"2742_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patamo E (2019) Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab 21:434\u2013438","journal-title":"Diabetes Obes Metab"},{"key":"2742_CR15","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.dsx.2019.04.035","volume":"13","author":"G Chawla","year":"2019","unstructured":"Chawla G, Chaudhary KK (2019) A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr 13:2001\u20132008","journal-title":"Diabetes Metab Syndr"},{"key":"2742_CR16","unstructured":"IUPHAR\/BPS guide to pharmacology (2026) https:\/\/www.guidetopharmacology.org Accessed 2 May"},{"key":"2742_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385\u2013396","journal-title":"Drug Saf"},{"key":"2742_CR18","doi-asserted-by":"crossref","unstructured":"Heisinger-Heidler T, Shannon R, Meyer T, Kamanzi S, Rosoklija I, Liu DB, Chu DI, Miller CH, Johnson EK Phimosis Treatment and Risk of Recurrent Urinary Tract Infection in Infant Males: A Systematic Review. Urology 2026:208:185\u2013192","DOI":"10.1016\/j.urology.2025.11.239"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02742-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:15:21Z","timestamp":1788232521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-026-02742-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2742"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02742-0","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares that there are no conflicts of interest relevant to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work was performed using the database, Vigibase\n                      \u00ae\n                      which is freely available to the author. None informed consent was required from patients since the database Vigibase\n                      \u00ae\n                      is anonymized. Institutional review board approval was not required because Vigibase\n                      \u00ae\n                      is an anonymized database open to pharmacovigilance centers. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}